PuSH - Publikationsserver des Helmholtz Zentrums München

Tschoep, K.* ; Kohlmann, A.* ; Schlemmer, M.* ; Haferlach, T.* ; Issels, R.D.

Gene expression profiling in sarcomas.

Crit. Rev. Oncol. Hematol. 63, 111-124 (2007)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Sarcomasnext term are a heterogeneous group of malignant mesenchymal tumors of difficult classification. There is considerable variability in both histological appearance and responsiveness to therapy. Their overall poor clinical prognosis is reflected by the fact that >65% of patients suffering retroperitoneal soft tissue previous termsarcomanext term die within 5 years [Heslin MJ, et al. Prognostic factors associated with long-term survival for retroperitoneal previous termsarcoma:next term implications for management. J Clin Oncol 1997;15(8):2832–9]. A greater understanding of the biology of previous termsarcomasnext term is needed in order to increase the potential for identifying new therapeutic targets and strategies.Microarray analysis permits a global approach to gene expression analysis of thousands of genes at the same time and has proven to be useful for further molecular characterization of tumor tissue and cell lines.This article provides a comprehensive review of possible new biomarkers identified in gene expression studies of previous termsarcomas.next term These markers give new insight into the pathogenesis of previous termsarcomas,next term such as malignant fibrous histiocytoma [Lee YF, et al. Molecular classification of synovial previous termsarcomas,next term leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. Br J Cancer 2003;88(4):510–5], allow a further subclassifcation of tumors like calponin-positive and calponin-negative leiomyosarcoma, or may help to predict treatment responsiveness and prognosis in patients based on an individual gene expression pattern. In some studies candidate targets for possible new treatment strategies were identified. For instance newly identified markers such as ERBB2 [Allander SV, et al. Expression profiling of synovial previous termsarcomanext term by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 2002;161(5):1587–95] and EGFR [Nielsen TO, et al. Molecular characterization of soft tissue tumours: a gene expression study. Lancet 2002;359(9314):1301–7] might lead to the possible therapeutic use of Trastuzumab, Gefitinib or Cetuximab in synovial previous termsarcoma,next term comparable to the use of tyrosine kinase inhibitor STI (Gleevec) that is the standard treatment today of CD117-positive gastrointestinal stromal tumors.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Sarcomanext term; Microarray; Gene expression profiling; Gastrointestinal stromal tumors
ISSN (print) / ISBN 1040-8428
e-ISSN 1040-8428
Zeitschrift Critical Reviews in Oncology / Hematology
Quellenangaben Band: 63, Heft: 2, Seiten: 111-124 Artikelnummer: , Supplement: ,
Verlag Elsevier
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) CCG Tumor Therapy with Hyperthermia (IMI-KTH)